The use of novel immunotherapies, especially immune checkpoint inhibitors including CTLA-4, PD-1 and others, as well as targeted BRAF and MEK inhibitors have significantly improved outcomes for many patients with metastatic melanoma. This evidence concerns the gene MAP2K7 and metastatic melanoma.